文献速递妇产影像技术与安全US

超声空化通过ROS介导线粒体凋亡逆转卵巢癌紫杉醇耐药

Sonocavitation-Induced Mitochondrial Dysfunction via ROS-Mediated Apoptosis for Paclitaxel-Resistant Ovarian Cancer Therapy.
PubMed 文献 · Ultrasound Med Biol · 2026-01-12

本研究在紫杉醇耐药卵巢癌细胞及移植瘤模型中,采用低强度聚焦超声联合微泡诱导声空化,评估其通过ROS介导线粒体功能障碍诱导凋亡的抗肿瘤作用。结果显示声空化可显著诱导耐药细胞凋亡、抑制移植瘤生长并延长生存,且ROS清除剂可部分逆转该效应,提示ROS为核心机制。

要点

  • 声空化可诱导紫杉醇耐药卵巢癌细胞凋亡,机制涉及ROS蓄积与线粒体功能障碍。
  • 耐药组织Bcl-2升高、Bax与Caspase-3降低,提示内源性凋亡通路受损。
  • 动物实验中声空化抑制肿瘤生长、延长生存且未引起系统性毒性。

核心结论

  • 声空化通过ROS介导线粒体功能障碍诱导紫杉醇耐药卵巢癌细胞凋亡,并具有良好安全性。
  • 研究支持声空化作为克服化疗耐药的潜在辅助策略。

研究设计与样本

  • 研究类型为实验研究,包括体外细胞实验与紫杉醇耐药卵巢癌移植瘤小鼠体内实验。
  • 体外采用低强度聚焦超声联合微泡对耐药细胞实施声空化处理。
  • 评估指标包括凋亡、ROS产生、线粒体形态、氧耗、ATP水平、线粒体膜电位及膜蛋白。
  • 体内实验评估肿瘤生长曲线、生存分析、血液学与器官组织学安全性。

关键影像表现/征象

  • 紫杉醇耐药卵巢癌组织Bcl-2升高、Bax与Caspase-3降低,提示内源性凋亡受损。
  • 声空化处理后耐药细胞凋亡显著增加。
  • 声空化导致线粒体体积减小、氧耗紊乱、ATP水平降低、膜电位崩溃及膜蛋白破坏。
  • 细胞色素c释放与cleaved Caspase-3激活证实线粒体依赖性凋亡发生。

诊断标准与关键数值

  • 耐药组织与敏感组织比较显示Bcl-2升高、Bax降低、Caspase-3降低。
  • 声空化处理后耐药细胞凋亡比例显著增加。
  • 声空化导致线粒体膜电位崩溃与线粒体膜蛋白破坏。
  • ROS清除剂部分逆转声空化效应,确认ROS蓄积为关键介导机制。

临床应用与阅片要点

  • 声空化具备作为紫杉醇耐药卵巢癌辅助治疗的潜在转化价值。
  • 超声参数需为低强度聚焦超声联合微泡的优化参数,具体数值原文未列出。

局限性

  • 原文未提及样本量、中心数、超声参数具体数值及统计阈值,缺乏可量化重复依据。
  • 本研究为临床前实验,向人体转化前仍需更多验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether sonocavitation, induced by low-intensity focused ultrasound combined with microbubbles, can overcome paclitaxel resistance in ovarian cancer by promoting apoptosis through reactive oxygen species (ROS)-mediated mitochondrial dysfunction.

METHODS: Paclitaxel-resistant ovarian cancer tissues and cell lines were compared with chemotherapy-sensitive counterparts for the expression of apoptosis-related proteins. Sonocavitation treatment was applied to resistant cells using optimized ultrasound parameters. Apoptosis, ROS production, mitochondrial morphology, oxygen consumption, mitochondrial membrane potential and mitochondrial membrane proteins were evaluated by flow cytometry, transmission electron microscopy, oxygen consumption assays, adenosine triphosphate (ATP) measurements, mitochondrial membrane potential assay kit staining and Western blotting. In vivo antitumor efficacy and biosafety were examined in paclitaxel-resistant xenograft mouse models, with tumor growth curves, survival analysis, and hematological/organ histology assessments.

RESULTS: Paclitaxel-resistant ovarian cancer tissues exhibited elevated Bcl-2 and reduced Bax and Caspase-3, indicating impaired intrinsic apoptosis. Sonocavitation significantly increased apoptosis in resistant ovarian cancer cells and induced marked mitochondrial dysfunction, including reduced mitochondrial size, disrupted oxygen consumption, decreased ATP levels, collapse of mitochondrial membrane potential and destruction of mitochondrial membrane proteins. Cytochrome c release and activation of cleaved Caspase-3 confirmed mitochondrial-dependent apoptosis. In vivo, sonocavitation suppressed tumor growth and prolonged survival without causing systemic toxicity. ROS scavengers partially reversed these effects, confirming that ROS accumulation is a key mediator of the therapeutic mechanism.

CONCLUSION: Sonocavitation induces apoptosis in paclitaxel-resistant ovarian cancer through ROS-mediated mitochondrial dysfunction and demonstrates effective tumor-suppressive activity with a favorable safety profile. These findings support sonocavitation as a promising adjuvant strategy to overcome chemoresistance and enhance ovarian cancer treatment outcomes.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Qiu, Xu, Wu, et al. Sonocavitation-Induced Mitochondrial Dysfunction via ROS-Mediated Apoptosis for Paclitaxel-Resistant Ovarian Cancer Therapy. Ultrasound Med Biol. 2026. PMID: 41530022. doi:10.1016/j.ultrasmedbio.2025.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。